FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy

Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis

Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint

AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy

Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil

European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC

Servier acquires Edgewise Therapeutics' muscular dystrophy business

Eisai reports new data showing etalanetug reduces Alzheimer's Disease tau tangle‑specific biomarker

Takeda and Indonesia launch partnership to expand plasma-derived medicine production

HDT Bio Launches Canadian clinical programme for brain cancer treatment

Antengene receives USD60m upfront payment from UCB

BioArctic's partner Eisai presents new clinical data on Leqembi subcutaneous autoinjector at AAIC 2026

FDA approves Sanofi's subcutaneous Sarclisa Escena as first anticancer therapy delivered via on-body injector

Nexstim expands Health Canada approval for NBS 6

Biohaven announces scientific leadership changes